1-(3-Cyclopropyl-5-trifluoromethylpyridin-2-yl)piperazine → HCID 71252926、化合物
反応式
[CH3:1][S:2]([C:5]1[CH:15]=[C:14]([N:16]2[C@H:20]([CH3:21])[CH2:19][CH2:18][S:17]2(=[O:23])=[O:22])[CH:13]=[CH:12][C:6]=1[C:7](OCC)=[O:8])(=[O:4])=[O:3].[CH:24]1([C:27]2[C:28]([N:37]3[CH2:42][CH2:41][NH:40][CH2:39][CH2:38]3)=[N:29][CH:30]=[C:31]([C:33]([F:36])([F:35])[F:34])[CH:32]=2)[CH2:26][CH2:25]1>>[CH:24]1([C:27]2[C:28]([N:37]3[CH2:42][CH2:41][N:40]([C:7]([C:6]4[CH:12]=[CH:13][C:14]([N:16]5[C@H:20]([CH3:21])[CH2:19][CH2:18][S:17]5(=[O:22])=[O:23])=[CH:15][C:5]=4[S:2]([CH3:1])(=[O:3])=[O:4])=[O:8])[CH2:39][CH2:38]3)=[N:29][CH:30]=[C:31]([C:33]([F:36])([F:34])[F:35])[CH:32]=2)[CH2:25][CH2:26]1参加物
3
実験手順
Using ethyl (R)-2-methanesulfonyl-4-(3-methyl-1,1-dioxo-1λ6-isothiazolidin-2-yl)benzoate (181 mg) described in Preparation Example 28 and 1-(3-cyclopropyl-5-trifluoromethylpyridin-2-yl)piperazine (136 mg) described in Preparation Example 90 and by the reaction and treatment in the same manner as in Example 109, the title compound (172 mg) was obtained.
後処理
- customdescribed in Preparation Example 90 and by the reaction and treatment in the same manner as in Example 109
出典と根拠
- ORDレコード
- ord-06a2988241c04068ba0523dfc1a9ab87
- 出典データセット
- uspto-grants-2014_08
- 特許番号
- US08816079B2
反応ノート
読み込み中…